Drug Trial Radar · NCT07717840
A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
164
Actual
Start
Jul 8, 2026
Primary completion
Oct 1, 2026
Study completion Aug 19, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Conditions
- RSV Respiratory Syncytial Virus
Interventions
AZD6489Biological
Participants will receive AZD6489 as a single intramuscular injection.
Licensed RSV vaccine #1Biological
Participants will receive licensed RSV vaccine #1 as a single intramuscular injection.
Licensed RSV vaccine #2Biological
Participants will receive licensed RSV vaccine #2 as a single intramuscular injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of immediate unsolicited adverse events (AEs)Time frame: 30 minutes post-study intervention
- Incidence of injection site and systemic solicited adverse reactions (ARs)Time frame: Day 1 through 7 days post-study intervention
- Incidence of unsolicited adverse events (AEs)Time frame: Day 1 through 28 days post-study intervention
- Incidence of serious adverse events (SAEs)Time frame: Day 1 to Day 365
- Incidence of adverse events of special interest (AESIs)Time frame: Day 1 to Day 365
- Incidence of medically attended adverse events (MAAEs)Time frame: Day 1 to Day 365
- RSV A nAb responses to AZD6489Time frame: Day 29
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Long Beach, California
Research Site
Rolling Hills Estates, California
Research Site
Chicago, Illinois
Research Site
Lenexa, Kansas
Research Site
Kansas City, Missouri
Research Site
Omaha, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.